全文获取类型
收费全文 | 307391篇 |
免费 | 17945篇 |
国内免费 | 475篇 |
专业分类
耳鼻咽喉 | 4314篇 |
儿科学 | 10601篇 |
妇产科学 | 10453篇 |
基础医学 | 46135篇 |
口腔科学 | 8020篇 |
临床医学 | 25115篇 |
内科学 | 58348篇 |
皮肤病学 | 6525篇 |
神经病学 | 21659篇 |
特种医学 | 11952篇 |
外国民族医学 | 47篇 |
外科学 | 48392篇 |
综合类 | 8239篇 |
现状与发展 | 1篇 |
一般理论 | 169篇 |
预防医学 | 20630篇 |
眼科学 | 7234篇 |
药学 | 21856篇 |
中国医学 | 857篇 |
肿瘤学 | 15264篇 |
出版年
2021年 | 2979篇 |
2019年 | 2712篇 |
2018年 | 4197篇 |
2017年 | 2976篇 |
2016年 | 3443篇 |
2015年 | 3854篇 |
2014年 | 5063篇 |
2013年 | 7818篇 |
2012年 | 9938篇 |
2011年 | 10315篇 |
2010年 | 6559篇 |
2009年 | 5926篇 |
2008年 | 9228篇 |
2007年 | 10084篇 |
2006年 | 9863篇 |
2005年 | 9452篇 |
2004年 | 9169篇 |
2003年 | 8557篇 |
2002年 | 8169篇 |
2001年 | 13398篇 |
2000年 | 13710篇 |
1999年 | 11474篇 |
1998年 | 3100篇 |
1997年 | 2835篇 |
1996年 | 2676篇 |
1995年 | 2598篇 |
1994年 | 2380篇 |
1992年 | 8330篇 |
1991年 | 8481篇 |
1990年 | 8288篇 |
1989年 | 8107篇 |
1988年 | 7332篇 |
1987年 | 7091篇 |
1986年 | 6752篇 |
1985年 | 6532篇 |
1984年 | 4781篇 |
1983年 | 4139篇 |
1982年 | 2482篇 |
1979年 | 4441篇 |
1978年 | 3238篇 |
1977年 | 2741篇 |
1976年 | 2509篇 |
1975年 | 2842篇 |
1974年 | 3362篇 |
1973年 | 3368篇 |
1972年 | 3121篇 |
1971年 | 2952篇 |
1970年 | 2847篇 |
1969年 | 2585篇 |
1968年 | 2543篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Hassen Lena M. Albarrak Rana A. Albahlal Reem A. Alsaqabi Dimah K. Hassen Ikhlass M. Daghestani Maha H. Alqurtas Eman M. Alkhalaf Abdulaziz T. Bedaiwi Mohammed K. Omair Mohammed A. Almaghlouth Ibrahim A. 《Quality of life research》2022,31(11):3229-3239
Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional... 相似文献
2.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
3.
Rajendrababu Sharmila Puthuran George Varghese Alia Laxmi Ananya Uduman Mohammed Sithiq Wijesinghe Hiruni Kaushalya 《International ophthalmology》2022,42(8):2609-2618
International Ophthalmology - To investigate the efficacy and safety of non-valved Aurolab aqueous drainage implant (AADI) surgery combined with phacoemulsification in eyes with refractory glaucoma... 相似文献
4.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
5.
6.
7.
8.
Elizabeth D. Krebs Robert B. Hawkins J. Hunter Mehaffey Clifford E. Fonner Alan M. Speir Mohammed A. Quader Jeffrey B. Rich Leora T. Yarboro Nicholas R. Teman Gorav Ailawadi 《The Journal of thoracic and cardiovascular surgery》2019,157(4):1533-1542.e2
Objectives
Expedient extubation after cardiac surgery has been associated with improved outcomes, leading to postoperative extubation frequently during overnight hours. However, recent evidence in a mixed medical-surgical intensive care unit population demonstrated worse outcomes with overnight extubation. This study investigated the impact of overnight extubation in a statewide, multicenter Society of Thoracic Surgeons database.Methods
Records from 39,812 patients undergoing coronary artery bypass grafting or valve operations (2008-2016) and extubated within 24 hours were stratified according to extubation time between 06:00 and 18:00 (day) or between 18:00 and 6:00 (overnight). Outcomes including reintubation, mortality, and composite morbidity-mortality were evaluated using hierarchical regression models adjusted for Society of Thoracic Surgeons predictive risk scores. To further analyze extubation during the night, a subanalysis stratified patients into 3 groups: 06:00 to 18:00, 18:00 to 24:00, and 24:00 to 06:00.Results
A total of 20,758 patients were extubated overnight (52.1%) and were slightly older (median age 66 vs 65 years, P < .001) with a longer duration of ventilation (4 vs 7 hours, P < .001). Day and overnight extubation were associated with equivalent operative mortality (1.7% vs 1.7%, P = .880), reintubation (3.7% vs 3.4%, P = .141), and composite morbidity-mortality (8.2% vs 8.0%, P = .314). After risk adjustment, overnight extubation was not associated with any difference in reintubation, mortality, or composite morbidity-mortality. On subanalysis, those extubated between 24:00 and 06:00 exhibited increased composite morbidity-mortality (odds ratio, 1.18; P = .001) but no difference in reintubation or mortality.Conclusions
Extubation overnight was not associated with increased mortality or reintubation. These results suggest that in the appropriate clinical setting, it is safe to routinely extubate cardiac surgery patients overnight. 相似文献9.
10.